NAV

Benactyzine

Identification

Generic Name
Benactyzine
DrugBank Accession Number
DB09023
Background

Benactyzine is an anticholinergic drug used as an antidepressant in the treatment of depression and associated anxiety.

Benactyzine is no longer widely used in medicine, although it is still a useful drug for scientific research. It does not possess any antihistamine properties.

Type
Small Molecule
Groups
Withdrawn
Structure
3D
Similar Structures
Weight
Average: 327.4174
Monoisotopic: 327.183443671
Chemical Formula
C20H25NO3
Synonyms
  • Benactyzine
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
1,2-BenzodiazepineThe risk or severity of CNS depression can be increased when Benactyzine is combined with 1,2-Benzodiazepine.
AcenocoumarolThe risk or severity of adverse effects can be increased when Benactyzine is combined with Acenocoumarol.
AcetazolamideThe risk or severity of CNS depression can be increased when Acetazolamide is combined with Benactyzine.
AcetophenazineThe risk or severity of CNS depression can be increased when Acetophenazine is combined with Benactyzine.
AclidiniumThe risk or severity of adverse effects can be increased when Benactyzine is combined with Aclidinium.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
International/Other Brands
Cedad / Cevanol / Deprol / Lucidil / Morcain / Nutinal / Parasan / Phebex / Phobex / Suavitil (Merck)

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Diphenylmethanes
Direct Parent
Diphenylmethanes
Alternative Parents
Tertiary alcohols / Trialkylamines / Carboxylic acid esters / Amino acids and derivatives / Monocarboxylic acids and derivatives / Organopnictogen compounds / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds / Aromatic alcohols
Substituents
Alcohol / Amine / Amino acid or derivatives / Aromatic alcohol / Aromatic homomonocyclic compound / Carbonyl group / Carboxylic acid derivative / Carboxylic acid ester / Diphenylmethane / Hydrocarbon derivative
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
595EG71R3F
CAS number
302-40-9
InChI Key
IVQOFBKHQCTVQV-UHFFFAOYSA-N
InChI
InChI=1S/C20H25NO3/c1-3-21(4-2)15-16-24-19(22)20(23,17-11-7-5-8-12-17)18-13-9-6-10-14-18/h5-14,23H,3-4,15-16H2,1-2H3
IUPAC Name
2-(diethylamino)ethyl 2-hydroxy-2,2-diphenylacetate
SMILES
CCN(CC)CCOC(=O)C(O)(C1=CC=CC=C1)C1=CC=CC=C1

References

Synthesis Reference

U.S. Patent 2,394,770.

General References
  1. McLaughlin B, Rickels K, Abidi M, Toro R: Meprobamate-benactyzine (Deprol) and placebo in two depressed outpatient populations. Psychosomatics. 1969 Mar-Apr;10(2):73-81. [Article]
KEGG Drug
D07498
PubChem Compound
9330
PubChem Substance
310264979
ChemSpider
8966
BindingDB
50144504
RxNav
1361
ChEBI
94775
ChEMBL
CHEMBL70352
ZINC
ZINC000001734034
Drugs.com
Drugs.com Drug Page
Wikipedia
Benactyzine

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)177-178 (Hydrochloride salt)U.S. Patent 2,394,770.
Predicted Properties
PropertyValueSource
Water Solubility0.188 mg/mLALOGPS
logP3.45ALOGPS
logP3.44Chemaxon
logS-3.2ALOGPS
pKa (Strongest Acidic)11.05Chemaxon
pKa (Strongest Basic)8.96Chemaxon
Physiological Charge1Chemaxon
Hydrogen Acceptor Count3Chemaxon
Hydrogen Donor Count1Chemaxon
Polar Surface Area49.77 Å2Chemaxon
Rotatable Bond Count9Chemaxon
Refractivity95.77 m3·mol-1Chemaxon
Polarizability36.65 Å3Chemaxon
Number of Rings2Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
MS/MS Spectrum - , positiveLC-MS/MSsplash10-004i-0309000000-31b1e744376b7dab1f25
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-03di-0049000000-071b8733a37c02d12f54
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0059-1927000000-c616779c752ea98be66f
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0o90-3962000000-b48bfb424d19c9ef1c0f
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-003r-0940000000-0d8be9428c930ba25900
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-001i-1910000000-fd8039d581f8e7af1bf8
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-05r0-6910000000-c55921ec4403483dc101
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-190.1110516
predicted
DarkChem Lite v0.1.0
[M-H]-175.02727
predicted
DeepCCS 1.0 (2019)
[M+H]+190.0807516
predicted
DarkChem Lite v0.1.0
[M+H]+177.38525
predicted
DeepCCS 1.0 (2019)
[M+Na]+190.0211516
predicted
DarkChem Lite v0.1.0
[M+Na]+184.02132
predicted
DeepCCS 1.0 (2019)

Drug created at June 25, 2014 17:30 / Updated at February 21, 2021 18:52